Edgewise Therapeutics Completes $95 Million Series C Financing to Advance Clinical Development of Muscular Dystrophy Program - Financing Round Led by Viking Global Investors - - Proceeds will fund ongoing clinical development of EDG-5506, a novel, oral drug candidate for Duchenne and Becker muscular dystrophy, as well as other rare muscle disease research programs - BOULDER, Colo., December 8, 2020-- Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing orally bioavailable, small molecule therapies for musculoskeletal diseases, today announced the closing of a $95 million Series C preferred stock financing led by Viking Global Investors.